Abstract:Cancer is a leading cause of human death worldwide. Commonly used methods of treatment such as surgery, radiation and chemotherapy tend to be largely successful but are extremely invasive and have serious toxic side effects. Thus, oncolytic viruses represent an attractive alternative to currently used anti-cancer treatments. Among different viral methods for gene delivery, vectors based on a human parvovirus, the adeno-associated virus (AAV) has attracted much attention mainly because of its non-pathogenic nature, and its ability to mediate long-term, sustained therapeutic gene expression. In current studies, AAV serotype 6 was identified to be particularly effective in transduction of several human prostate (PC3), breast (T47D) and liver (Huh7) cancer cell. We also found that transduction efficiency of these vectors can be significantly improved, up to 5-fold, by site-direct mutagenesis of surface exposed residues involved in intracellular trafficking. Over thirty single and multiple tyrosine (Y), serine (S), threonine (T) capsid mutants were developed and AAV6-Y705-731F+T492V was identified the most efficient. However, promiscuity of the AAV vectors makes it difficult to use in vivo. The recent studies on AAV crystal structure have identified specific regions of the capsid which are surface-exposed and tolerant to insertion of the peptides. In the current studies, we developed novel AAV-based vectors for targeting of human cancer cells by incorporating Arg-Gly-Asp (RGD) containing peptide to enable AAV to infect integrin-expressing cells. These AAV6-RGD vectors improve transduction efficiency approximately 3-fold compared with wild-type AAV6 vectors by enhancing viral entry to the cells. We correlated increased transduction efficiency with levels of expression of avβ5 integrin. The combination of RGD-peptide and mutations of surface-exposed residues on a single AAV6 capsid, further increases transduction efficiency up to approximately 10-fold. We next used qPCR analysis to quantitate the vector genomes in cytoplasmic and nuclear fractions of cells infected with the WT and the mutant AAV6 vectors at different time points. We showed that the increase in the transduction efficiency of the AAV6-Y705-731F+T492V vector correlated well with the improvement of both the entry and nuclear translocation of the vectors, compared with AAV6-WT. To conduct animal studies, we also introduced an additional mutation at lysine (K531E) since this was shown to impair the ability of vectors to bind to heparan sulfate proteoglycan and thus decrease the affinity to mice hepatocytes. We used a xenograft animal model in immune-deficient mice to prove the specificity and high transduction efficiency of AAV6-RGD-Y705-731F+T492V-K531E vectors in vivo. In summary, this approach can potentially lead to the development of therapeutic AAV vectors with selective tropism and high transduction efficiency of human cancer cells.

[The Construction of Recombinant AAV Vector Expressing HSVtk Gene Controlled by Tet-On and the Detection of Its Activity].

Construction, Packaging and Titration of Recombinant Adeno-Associated Virus Vectors Contaning Antitumor Genes

Establishment of A Recombinant Adeno-Associated Virus Expressing Hvegf(165)

Construction and Identification of Recombinant Adeno- Associated Virus Vector Co-Expressing Human Vascular Endothelial Growth Factor and Green Fluorescent Protein

Construction and Identification of Recombinant Adeno-Associated Virus Vector Harboring Fusion Gene NT4-Apoptin-HA2-TAT

Construction of a gengeral adeno-associated virus vector and GFP expression in rat NIH3T3 transduced by the rAAV vector

Construction of Recombinant Adeno-Associated Virus Vector Co-Expressing Hvegf165 and Hbmp7 Gene

Construction of Retroviral Vector Carrying HSV-tk Gene under Control of Human AFP Enhancer Core Sequence and Human Pgk Promotor.

[Construction and Identification of Recombinant Vectors Carrying Herpes Simplex Virus Thymidine Kinase Genes Expressed in Vascular Endothelial Cells].

Establishment of an AAV Reverse Infection-Based Array

313. Development of the AAV6-Based Vectors with Selective Tropism and High Transduction Efficiency of Human Cancer Cells

Rerovirus Mediated Hsv-Tk Gene Transfer Can Influence The Function Of Human T-Lymphocyte

Tetracycline controlled DT/VEGF system gene therapy mediated by adenovirus vector

Construction of Recombinant Retrovirus Vector Bearing Antisense AFP Enhancer/tk Gene and Its Hepatocyte-Specific Expression

[A Novel Packaging System of Recombinant AAV5/5 Vector].

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

Homologous Recombination-Based Adenovirus Vector System for Tumor Cell-Specific Gene Delivery

Study on the Construction of Recombinant AAV Vector Mediated Tumstatin Gene and Its Activity

Enhanced Transgene Expression from Recombinant Single-Stranded D-sequence-substituted Adeno-Associated Virus Vectors in Human Cell Lines in Vitro and in Murine Hepatocytes in Vivo.

Construction of eukaryotic expression vector containing HSV-TK and IL-2 double genes and its expression in human pulmonary adenocarcinoma cell A549.

Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery.